Institutional Ownership Data

Biotech Specialist Hedge Fund Positions

Cleaned and structured 13D/13G ownership disclosures and 13F institutional holdings for biotech-focused funds. New positions, stake reductions, and activist crossings, linked to company and trial identifiers.

Request dataset →

Live Sample

What the data looks like

Live data from our pipeline.

Altimmune, Inc. ALT May 1

RA Capital Management

6.5% New position SC 13G
Acrivon Therapeutics, Inc. ACRV Apr 23

RA Capital Management

28.8% ↑7.2% SC 13D/A
Spyre Therapeutics, Inc. SYRE Apr 22

Perceptive Advisors

5.0% ↑0.6% SC 13G
Bright Minds Biosciences Pty Ltd DRUG Apr 30

Cormorant Asset Management, LP

9.7% ↓1.2% SC 13G/A
Adicet Bio, Inc. ACET Apr 13

RA Capital Management

12.3% ↑2.4% SC 13G/A

Live data from our pipeline. The structured export includes all fields listed below.

Use Cases

Who Uses This Data

Structured for direct analysis — no data cleaning, no manual joins required.

Investors and Quantitative Analysts

  • ● Track when biotech-focused funds cross ownership thresholds or change ownership intent (13D)
  • ● Screen for multi-fund convergence on the same company as a conviction indicator
  • ● Export clean historical position data for quantitative models without manual EDGAR parsing
  • ● Cross-reference fund moves with trial events and 8-K signals in your own system

Investor Relations and Corporate Strategy

  • ● Identify specialists active in your therapeutic area
  • ● Track peer company institutional ownership trends for competitive IR positioning
  • ● Prepare for shareholder conversations with current and historical ownership structure data

What's Included

Data Fields

Primary Sources

  • • SEC EDGAR Schedule 13D and 13G filings
  • • SEC EDGAR Form 13F institutional holdings
  • • 500+ tracked public biotech companies with CIK, ticker, CUSIP

Fields Include

  • • Fund name and SEC CIK
  • • Company name, ticker, CIK, and CUSIP
  • • Filing type (13D active, 13G passive, 13F holdings)
  • • Filing date and period of report
  • • Shares held and ownership percentage
  • • Change type (new position, increase, decrease, exit)
  • • Change percentage versus prior period
  • • Activist vs. passive distinction (13D vs. 13G)
  • • Linked trial count and therapeutic area per company

Get the Data

or email [email protected]